(Q38217477)

31 August 2017

title

Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines). (English)

1 reference

31 August 2017

1 reference

Min Li-Weber

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

11 June 2014

1 reference

International Journal of Cancer

31 August 2017

published in

1 reference

31 August 2017

volume

137

1 reference

31 August 2017

issue

8

1 reference

31 August 2017

page(s)

1791-1799

1 reference

Aglaia (Meliaceae): an evaluation of taxonomic concepts based on DNA data and secondary metabolites

31 August 2017

cites work

1 reference

Insecticidal rocaglamide derivatives from Aglaia spectabilis (Meliaceae).

21 January 2018

1 reference

Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy.

21 January 2018

1 reference

Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae)

21 January 2018

1 reference

The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities

21 January 2018

1 reference

A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.

21 January 2018

1 reference

Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27

21 January 2018

1 reference

The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression

21 January 2018

1 reference

Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata

21 January 2018

1 reference

Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica.

21 January 2018

1 reference

Translational control in cancer.

21 January 2018

1 reference

The biological and therapeutic relevance of mRNA translation in cancer

21 January 2018

1 reference

Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression

21 January 2018

1 reference

The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2

21 January 2018

1 reference

Ras-Raf signaling needs prohibitin

21 January 2018

1 reference

"Prohibitin"g CRAF/MAPK activation with rocaglamides.

21 January 2018

1 reference

Prohibitins Are Required for Cancer Cell Proliferation and Adhesion

21 January 2018

1 reference

Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol

21 January 2018

1 reference

Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II.

21 January 2018

1 reference

Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex

21 January 2018

1 reference

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors

21 January 2018

1 reference

Rapid destruction of human Cdc25A in response to DNA damage

21 January 2018

1 reference

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

21 January 2018

1 reference

Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability

21 January 2018

1 reference

The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints

21 January 2018

1 reference

Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis

21 January 2018

1 reference

CDC25 phosphatases in cancer cells: key players? Good targets?

21 January 2018

1 reference

ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling

21 January 2018

1 reference

ATR: an essential regulator of genome integrity

21 January 2018

1 reference

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer

21 January 2018

1 reference

Flavaglines: a group of efficient growth inhibitors block cell cycle progression and induce apoptosis in colorectal cancer cells

21 January 2018

1 reference

Map kinase signaling pathways and hematologic malignancies

21 January 2018

1 reference

p38 MAP kinase: a convergence point in cancer therapy

21 January 2018

1 reference

Cell cycle, CDKs and cancer: a changing paradigm

21 January 2018

1 reference

Cyclin D as a therapeutic target in cancer

21 January 2018

1 reference

Cdc25 phosphatases and cancer

21 January 2018

1 reference

Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases

21 January 2018

1 reference

CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability

21 January 2018

1 reference

Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state

21 January 2018

1 reference

TXNIP regulates peripheral glucose metabolism in humans

21 January 2018

1 reference

Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression

21 January 2018

1 reference

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

21 January 2018

1 reference

p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide

21 January 2018

1 reference

Differential involvement of p38 MAP kinase pathway and Bax translocation in the mitochondria-mediated cell death in TCR- and dexamethasone-stimulated thymocytes.

21 January 2018

1 reference

JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells

21 January 2018

1 reference

p38 MAPK downregulates phosphorylation of Bad in doxorubicin-induced endothelial apoptosis

21 January 2018

1 reference

Mcl-1 is a potential therapeutic target in multiple types of cancer

21 January 2018

1 reference

Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity

21 January 2018

1 reference

21 January 2018

1 reference

Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris

21 January 2018

1 reference

Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression

21 January 2018

1 reference

The TRAIL apoptotic pathway in cancer onset, progression and therapy

21 January 2018

1 reference

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

21 January 2018

1 reference

Life and death in peripheral T cells

21 January 2018

1 reference

IAP proteins as targets for drug development in oncology

21 January 2018

1 reference

HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP).

21 January 2018

1 reference

XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells

21 January 2018

1 reference

c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis

21 January 2018

1 reference

Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail

21 January 2018

1 reference

PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability

21 January 2018

1 reference

Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas

21 January 2018

1 reference

Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system

21 January 2018

1 reference

Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

21 January 2018

1 reference

Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis

21 January 2018

1 reference

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

Tumour cell survival signalling by the ERK1/2 pathway

21 January 2018

1 reference

Raf kinases in cancer-roles and therapeutic opportunities

21 January 2018

1 reference

RAS oncogenes: weaving a tumorigenic web

21 January 2018

1 reference

The role and therapeutic potential of prohibitin in disease

21 January 2018

1 reference

Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.

21 January 2018

1 reference

Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis

21 January 2018

1 reference

Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis

21 January 2018

1 reference

High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer

21 January 2018

1 reference

HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers

21 January 2018

1 reference

Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo.

21 January 2018

1 reference

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management

21 January 2018

1 reference

Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent

21 January 2018

1 reference

Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression

21 January 2018

1 reference

Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia

21 January 2018

1 reference

PUMA, a potent killer with or without p53

21 January 2018

1 reference

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

21 January 2018

1 reference

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

21 January 2018

1 reference

Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression

21 January 2018

1 reference

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

21 January 2018

1 reference

Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence

21 January 2018

1 reference

21 January 2018

Surfing the p53 network

1 reference

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53

21 January 2018

1 reference

Apoptosis in heart failure. -The role of the β-adrenergic receptor-mediated signaling pathway and p53-mediated signaling pathway in the apoptosis of cardiomyocytes-.

21 January 2018

1 reference

Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity

21 January 2018

1 reference

A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide.

21 January 2018

1 reference

p53 in neuronal apoptosis

21 January 2018

1 reference

The p53 family in nervous system development and disease

21 January 2018

1 reference

Bcl-2 Phosphorylation by p38 MAPK

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29013

1 reference

31 August 2017

1 reference